Vanguard Pharma and Biotech (00399.HK) announced the mutual termination of its share subscription agreement following extensive negotiations. The decision stems from the subscriber's failure to fulfill obligations under the original agreement, coupled with current market conditions. On July 15, 2025, both parties executed a termination deed to formally dissolve the subscription arrangement.

This termination extinguishes all associated rights, benefits, obligations, and liabilities effective immediately from the execution date. Crucially, the agreement stipulates that neither party may pursue claims against the other regarding any matters arising from or related to the now-nullified subscription contract. The company cited evolving market dynamics and the counterparty's non-performance as primary factors driving this strategic withdrawal from the capital-raising initiative.